 |
|
|
| |
Subgroup Analyses From DRIVE-FORWARD, a Phase 3
Trial of Doravirine Versus Ritonavir-Boosted
Darunavir in Treatment-Naïve HIV-1-Infected
Participants at Week 48
|
| |
| |
Reported by Jules Levin
EACS - 16th European Aids Conference
Milano
October 26, 2017
Molina J-M1; Squires K2; Sax PE3; Cahn P4; Lombaard J5; DeJesus E6; Xu X7; Rodgers A7;
Lupinacci L7, Kumar S7; Sklar P7; Nguyen B-Y7; Hanna G7; Hwang C7 for the DRIVE-FORWARD
Study Group
1University of Paris 7 and Hôpital Saint-Louis, Paris, France; 2Thomas Jefferson University, Philadelphia, PA, USA; 3Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA; 4Fundación Huesped, Buenos Aires, Argentina; 5Josha Research, Bloemfontein, South Africa; 6Orlando Immunology Center, Orlando, FL, USA; 7Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
